진료분야

• 비뇨기암,뇌종양,소아뇌종양,두경부암,피부암

학력

• 서울대학교 의과대학 의학사 (2012)
• 서울대학교 대학원 의학과 방사선종양학 의학박사 (2019)

경력

• 2023.03-현재 연세암병원 방사선종양학과 임상조교수
• 2021.03-2023.02 서울특별시 보라매병원 방사선종양학과 임상조교수
• 2019.09-2021.02 서울특별시 보라매병원 방사선종양학과 진료조교수
• 2018.07-2019.08 분당서울대학교병원 방사선종양학과 진료조교수
• 2018.03-2018.06 분당서울대학교병원 방사선종양학과 전임의
• 2017.03-2018.02 서울대학교병원 방사선종양학과 전임의
• 2013.03-2017.02 서울대학교병원 방사선종양학과 전공의
• 2012.03-2013.02 서울대학교병원 수련의

학술활동

• 대한방사선종양학회 정회원
• 대한암학회 평생회원
• 대한신경종양학회 정회원
• 대한소아뇌종양학회 정회원
• 대한두경부종양학회 정회원
• 대한종양내과학회 정회원
• 대한방사선방어학회 평생회원
• 미국신경종양학회 정회원
• 2015.04 한국임상암학회 우수포스터상
• 2016.05 한국암학술재단 학술상
• 2016.10 대한방사선종양학회 우수전시상
• 2016.10 대한방사선종양학회 HDX 전공의 해외학회 발표지원상
• 2017.09 미국방사선종양학회 (ASTRO) 전공의 우수포스터상, 임상부문
• 2017.11 아시아방사선종양학회 (FARO) 우수 구연발표 travel grant
• 2018.06 대한암학회 Merit Award, 최우수 연제상
• 2018.06 아시아방사선종양학회 (FARO) 우수 구연발표 travel grant
• 2019.11 아시아방사선종양학회 (FARO) 우수 구연발표 travel grant
• 2020.11 대한암학회 Merit Award, 우수 연제상
• 2022.09 대한종양내과학회 젊은연구자상

주요업적

1. Wee CW, Keam B, Heo DS, Sung MW, Won TB, Wu HG. Locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy plus concurrent weekly cisplatin with or without neoadjuvant chemotherapy. Radiat Oncol J 2015; 33(2): 98-108. 2. Wee CW, Sung W, Kang HC, Cho KH, Han TJ, Jeong BK, Jeong JU, Kim H, Kim IA, Kim JH, Kim SH, Kim S, Lee DS, Lee MY, Lim do H, Park HL, Suh CO, Yoon SM, Kim IH. Evaluation of variability in target volume delineation for newly diagnosed glioblastoma: a multi-institutional study from the Korean Radiation Oncology Group. Radiat Oncol 2015; 10: 137. (IF 4.309) 3. Wee CW, Kim K, Chie EK, Yu SJ, Kim YJ, Yoon JH. Prognostic stratification and nomogram for survival prediction in hepatocellular carcinoma patients treated with radiotherapy for lymph node metastasis. Br J Radiol 2016; 89: 20160383. (IF 3.629) 4. Wee CW, Kim E, Kim N, Kim IA, Kim TM, Kim YJ, Park CK, Kim JW, Kim CY, Choi SH, Kim JH, Park SH, Choe G, Lee ST, Chang JH, Kim SH, Suh CO, Kim IH. Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: a multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. Radiother Oncol 2017; 123(1): 106-111. (IF 6.901) 5. Wee CW, Kim E, Kim TM, Park CK, Kim JW, Choi SH, Yoo RE, Lee ST, Kim IH. Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy. J Neurooncol 2017; 134(1): 169-175. (IF 4.506) 6. Wee CW, Kang HC, Wu HG, Chie EK, Choi N, Park JM, Kim JI, Huang CM, Wang JY, Ng SY, Goodman KA. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled-analysis of acute toxicity. Jpn J Clin Oncol 2018; 48(5): 458-466. (IF 2.925) 7. Wee CW, An HJ, Kang HC, Kim HJ, Wu HG. Variability of gross tumor volume delineation for stereotactic body radiotherapy of the lung with tri-60Co magnetic resonance image-guided radiotherapy system (ViewRay): a comparative study with magnetic resonance- and computed tomography- based target delineation. Technol Cancer Res Treat 2018; 17: 1-7. (IF 2.876) 8. Wee CW, Kim IH, Park CK, Kim JW, Dho YS, Ohka F, Aoki K, Motomura K, Natsume A, Kim N, Suh CO, Chang JH, Kim SH, Cho WK, Lim DH, Nam DH, Choi JW, Kim IA, Kim CY, Oh YT, Cho O, Chung WK, Kim SH, Kim E. Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: a multi-institutional collaborative study. Radiother Oncol 2018; 129(2): 347-351. (IF 6.901) 9. Wee CW, Kim JH, Kim HJ, Kang HC, Suh SY, Shin BS, Ma E, Kim IH. Radiosensitization of Glioblastoma Cells by a Novel DNA Methyltransferase-inhibiting Phthalimido-Alkanamide Derivative. Anticancer Res 2019; 39(2): 759-769. (IF 2.480) 10. Wee CW, Kim JH, Kim HJ, Kang HC, Suh SY, Shin BS, Ma E, Kim IH. Psammaplin A-Modified Novel Radiosensitizers for Human Lung Cancer and Glioblastoma Cells. J Radiat Prot Res 2019; 44(1): 15?25. 11. Wee CW, Kim IH, Park CK, Kim JW. Interim tumor progression and volumetric changes of surgical cavities during the surgery-to-radiotherapy interval in anaplastic gliomas: implications for additional pre-radiotherapy magnetic resonance imaging. Cancer Res Treat 2020; 52(2): 524-529. (IF 5.036) 12. Wee CW, Kim KS, Kim CY, Han JH, Kim YJ, Kim IA. Feasibility of Hippocampus-sparing VMAT for Newly Diagnosed Glioblastoma Treated by Chemoradiation: Pattern of Failure Analysis. Radiat Oncol 2020; 15(1): 98. (IF 4.309) 13. Wee CW, Kim IH, Park CK, Kim N, Suh CO, Chang JH, Lim DH, Nam DH, Kim IA, Kim CY, Oh YT, Chung WK, Kim SH. Chemoradiation in elderly patients with glioblastoma from the GBM-molRPA cohort: Is short-course radiotherapy enough or is it a matter of selection? J Neurooncol 2020; 148(1): 57-65. (IF 4.506) 14. Wee CW, Kim IH, Park CK, Lim DH, Nam DH, Yoon HI, Suh CO, Chang JH, Chung WK, Jung TY, Park SH, Kim CY, Kim YZ, Gwak HS, Cho KH, Kim JH, Im JH, Kim WC, Kim SH, Kim IA. Postoperative radiotherapy for WHO grade II?III intracranial ependymoma in adults: An intergroup collaborative study (KROG 18-06/KNOG 18-01). Radiother Oncol 2020; 150: 4-11. (IF 6.901) 15. Wee CW, Kim JH, Kim HJ, Kang HC, Suh SY, Shin BS, Ma E, Kim IH. Newly synthesized DNA methyltransferase inhibitors as radiosensitizers for human lung cancer and glioblastoma cells. Anticancer Res 2021; 41(2): 757-764. (IF 2.480) 16. Wee CW, Jang BS, Kim JH, Jeong CW, Kwak C, Kim HH, Ku JH, Kim SH, Cho JY, Kim SY. Prediction of pathologic findings with MRI-based clinical staging using the Bayesian network modeling in prostate cancer: a radiation oncologist perspective. Cancer Res Treat 2022; 54(1): 234-244. (IF 5.036) 17. Kim DY, Wu HG, Kim JH, Lee JH, Ahn SH, Chung EJ, Eom KY, Jung YH, Jeong WJ, Kwon TK, Kim S, Wee CW. Radiotherapy versus Surgery in Early-Stage HPV-positive Oropharyngeal Cancer. Cancer Res Treat 2022; 52(2): 406-416. (IF 5.036) 18. Wee CW. Radiotherapy for Newly Diagnosed Glioblastoma in the Elderly: What Is the Standard? Brain Tumor Res Treat 2022; 10(1): 12?21. 19. Han MG, Wee CW, Kang MH, Kim MJ, Jeon SH, Kim IA. Combination of OX40 Co-stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-negative Breast Cancer Model. Cancers 2022; 14: 2692. (IF 6.575) 20. Wee CW, Lee HJ, Lee JR, Lee H, Kwoen MJ, Jeong WJ, Eom KY. Effect of national oral health screening program on the risk of head and neck cancer: a Korean national population-based study. Cancer Res Treat 2022; 54(3): 709-718. (IF 5.036) 21. Byun HK, Chang WI, Lee JH, Park CK, Kim IA, Kim CY, Cho J, Kim EH, Chang JH, Kang SG, Moon JH, Lee SH, Kim IH, Suh CO, Wee CW, Yoon HI. Adjuvant Radiotherapy Versus Surveillance for Grade 2 Intracranial Meningiomas: A Multi-Institutional Propensity Score-matched Study. Front Oncol 2022; 12: 877244. (IF 5.738) 22. Wee CW, Yoon HI, Lee SW, Lim DH. Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the Brain Tumor Committee of the Korean Radiation Oncology Group (KROG 21-05). Jpn J Clin Oncol 2022; 52(8): 835-841. (IF 2.925) 23. Kim D, Chang WI, Byun HK, Kim IA, Cho J, Lee JH, Yoon HI, Wee CW. Dose-response relationship in patients with newly diagnosed atypical meningioma treated with adjuvant radiotherapy. J Neurooncol 2023; 161: 329-337. 24. Chang WI, Byun HK, Lee JH, Park CK, Kim IA, Kim CY, Chang JH, Kang SG, Lee SH, Kuranari Y, Tamura R, Toda M, Wee CW, Yoon HI. Novel postoperative serum biomarkers in atypical meningiomas: A multicenter study. Neurosurgery 2023 [Online ahead of print] 25. Park JB, Wu HG, Kim JH, Lee JH, Ahn SH, Chung EJ, Eom KY, Jeong WJ, Kwon TK, Kim S, Wee CW. Adjuvant Radiotherapy in Node-Negative Salivary Malignancies of the Parotid Gland: A Multi-institutional Analysis. Radiother Oncol 2023 [Online ahead of print]